Pirfenidone in respirable powder form for the treatment of pulmonary fibrosis: a safer alternative to the current oral delivery system?

Author： Onoue Satomi   Yamada Satomi  

Publisher： Future Science

ISSN： 2041-5990

Source： Therapeutic Delivery, Vol.4, Iss.8, 2013-08, pp. : 887-889

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pirfenidone: In Idiopathic Pulmonary Fibrosis

By Carter Natalie J.  

Drugs, Vol. 71, Iss. 13, 2011-09 ,pp. : 1721-1732

Adis International

Access to resources Recommend Favorite

Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation

By Antoniu Sabina A  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 11, 2005-11 ,pp. : 1443-1447

Informa Healthcare

Access to resources Recommend Favorite

Pirfenidone: a guide to its use in idiopathic pulmonary fibrosis

By Keating Gillian M.   Lyseng-Williamson Katherine A.   Carter Natalie J.  

Drugs & Therapy Perspectives, Vol. 28, Iss. 7, 2012-07 ,pp. : 10-13

Adis International

Access to resources Recommend Favorite

Current and Future Treatment Options in Idiopathic Pulmonary Fibrosis

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 9, Iss. 3, 2010-07 ,pp. : 158-172

Bentham Science Publishers

Access to resources Recommend Favorite

Dry Powder form of Polymeric Nanoparticles for Pulmonary Drug Delivery

By  

Current Pharmaceutical Design, Vol. 22, Iss. 17, 2016-05 ,pp. : 2549-2560

Bentham Science Publishers

Access to resources Recommend Favorite